anlotinib + utidelone

Anlotinib + utidelone is a combination therapy consisting of two distinct agents used in oncology. Anlotinib is a small-molecule multi-targeted tyrosine kinase inhibitor with anti-angiogenic properties, primarily inhibiting vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit, thereby suppressing tumor angiogenesis and proliferation. Utidelone is a novel epothilone-class microtubule inhibitor that stabilizes microtubules, disrupting mitosis and inducing apoptosis in cancer cells; it has demonstrated the ability to evade common resistance mechanisms associated with taxanes due to its unique binding site and lack of interaction with P-glycoprotein. The combination has shown antitumor activity in patients with advanced or metastatic cancers, including hormone receptor-positive/HER2-negative metastatic breast cancer with brain metastases and advanced esophageal cancer[1][2][3][4]. This regimen leverages the synergistic effects of anti-angiogenic therapy (anlotinib) and cytotoxic chemotherapy (utidelone).

Other names

Catequentinib